Patents Assigned to MEDSHINE DISCOVERY INC.
  • CRYSTAL FORM OF EGFR INHIBITOR AND PREPARATION METHOD THEREOF
    Publication number: 20220194959
    Abstract: Disclosed are a crystal form of an EGFR inhibitor and a preparation method thereof. Further disclosed is an application of the crystal form in preparing a drug for treating non-small cell lung cancer, especially an application in preparing a drug for treating non-small cell lung cancer with brain metastases.
    Type: Application
    Filed: April 10, 2020
    Publication date: June 23, 2022
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Xile LIU, Lu ZHANG, Charles Z. DING, Shuhui CHEN, Lihong HU
  • COMPOUNDS HAVING BOTH EFFECTS OF BET BROMODOMAIN PROTEIN INHIBITION AND PD-L1 GENE REGULATION
    Publication number: 20220177490
    Abstract: Compounds having both BET bromodomain protein inhibitory activity and PD-L1 gene expression regulation, and use thereof in preparing medicaments for treating tumor diseases related to BET bromodomain protein inhibition and PD-L1 gene expression. Specifically disclosed are a compound as shown in formula (1), and an isomer and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 6, 2020
    Publication date: June 9, 2022
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Chunli SHEN, Yuchuan ZHU, Ting WANG, Chengde WU, Shuhui CHEN
  • Benzopyrazole compound used as RHO kinase inhibitor
    Patent number: 11345678
    Abstract: The invention relates to a benzopyrazole compound used as RHO kinase inhibitor, a pharmaceutical composition and uses thereof for preparing an RHO kinase inhibiting drug, and more specifically to said compound of formula (I-1), a pharmaceutically acceptable salt and isomer thereof.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: May 31, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Lingyun Wu, Jun Yin, Cailin Wang, Zheming Xiao, Jian Li, Shuhui Chen
  • GLUCOSIDE DERIVATIVE THAT ACTS AS SGLT1 INHIBITOR AND APPLICATION THEREOF
    Publication number: 20220153772
    Abstract: A glucoside derivative that acts as an SGLT1 inhibitor and an application thereof in the preparation of a drug for SGLT1 related diseases. Specifically disclosed is a compound represented by formula (II), a tautomer thereof or a pharmaceutically acceptable composition thereof.
    Type: Application
    Filed: March 30, 2020
    Publication date: May 19, 2022
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Yi LI, Tao YU, Qinghua MAO, Chengde WU, Shuhui CHEN
  • Crystal form of 1H-imidazo[4,5-b]pyridine-2(3H)-one compound and preparation process therefor
    Patent number: 11325907
    Abstract: Disclosed are a crystal form of 1H-imidazo[4,5-b]pyridine-2(3H)-one compound and a preparation process therefor, and use of the crystal form in the manufacture of a medicament for treating a disease associated with PDE4 receptor.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: May 10, 2022
    Assignee: Medshine Discovery Inc.
    Inventors: Maoyi Lei, Yu Xu, Yunfu Luo
  • Tricyclic furan-substituted piperidinedione compound
    Patent number: 11319330
    Abstract: Disclosed are a series of tricyclic furan-substituted piperidinedione compounds and an application thereof in preparing a drug for treating a disease related to CRBN protein. In particular, disclosed is a derivative compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: May 3, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Maoyi Lei, Yunfu Luo, Yu Xu, Guoli Zhang, Jinghong Dong, Jian Li, Shuhui Chen
  • Salt and crystal form of modified andrographolide compound and preparation method thereof
    Patent number: 11299482
    Abstract: The present invention provides a salt and crystal form of a modified andrographolide compound and a preparation method and pharmaceutical use thereof.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: April 12, 2022
    Assignees: Medshine Discovery, Inc., Heilongjiang Zhenbaodao Pharmaceutical Co, LTD
    Inventors: Jianhua Xia, Zhigan Jiang, Haiying He, Jing Wang
  • Prostacyclin receptor agonist
    Patent number: 11299475
    Abstract: A compound represented by formula (I) or an isomer or a pharmaceutically acceptable salt thereof. The present invention also relates to an application of the same in preparing a drug for treating a disease related to a PGI2 receptor.
    Type: Grant
    Filed: February 2, 2019
    Date of Patent: April 12, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Wenyuan Qian, Chundao Yang, Guanghai Xu, Jian Li, Shuhui Chen
  • Compound as GLS1 inhibitor
    Patent number: 11254666
    Abstract: A compound as a GLS1 inhibitor as represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: February 22, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Yonggang Liao, Chaonan Liu, Changqing Wei, Hao Wu, Shuhui Chen
  • Substituted 1,3,4-thiadiazoles as GLS1 inhibitors
    Patent number: 11230544
    Abstract: Disclosed is to a thiadiazole derivative and the uses thereof in preparing a drug for treating GLS1-associated diseases. Specifically disclosed is a derivative compound of formula (I), a tautomer thereof or a pharmaceutically acceptable composition thereof.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: January 25, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Yonggang Liao, Jun Lin, Chaonan Liu, Changqing Wei, Wenyuan Qian, Chen Zhang, Zhen Gong, Jian Li, Shuhui Chen
  • Quinolino-pyrrolidin-2-one derivative and application thereof
    Patent number: 11230549
    Abstract: Disclosed are a series of quinolino-pyrrolidin-2-one compounds, and application thereof in preparation of drugs for ATM inhibitor-related diseases. The present disclosure specifically relates to a derivative compound represented by formula (I), tautomers thereof or pharmaceutically acceptable compositions thereof.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: January 25, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Wenyuan Qian, Chundao Yang, Guoqiang Dai, Jian Li, Shuhui Chen
  • 3,9-DIAZASPIRO[5,5]UNDECANE COMPOUND AS FLT3 AND AXL INHIBITORS
    Publication number: 20210395252
    Abstract: Disclosed in the present invention is a novel compound as FLT3 and AXL inhibitors. Specifically, disclosed are a compound represented by formula (I) and a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: September 27, 2019
    Publication date: December 23, 2021
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Xiangyu FU, Charles Z. DING, Lihong HU, Jianyu LU, Wen JIANG, Jian LI, Shuhui CHEN
  • Crystal form and salt form of pyridone compound and preparation method therefor
    Patent number: 11198686
    Abstract: A crystal form of a compound 1 and a method for preparing the same, further comprising an application of the crystal form in the preparation of a drug for treating diseases associated with fibrosis.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: December 14, 2021
    Assignees: GUANGZHOU JOYO PHARMATECH CO., LTD., SHLIAZHUANG SAGACITY NEW DRUG DEVELOPMENT CO., LTD., MEDSHINE DISCOVERY INC.
    Inventors: Lei Zhang, Bin Chen, Yangguang Zhao, Jian Li, Shuhui Chen
  • S1P1 agonist and application thereof
    Patent number: 11192886
    Abstract: The present invention relates to a class of tricyclic compounds and an application thereof as a sphingosine 1-phosphate type 1 (S1P1) receptor agonist. The invention specifically relates to a compound represented by formula (II), and a tautomer and pharmaceutically acceptable salt of same.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: December 7, 2021
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Lingyun Wu, Peng Zhang, Jian Li, Shuhui Chen
  • URACIL COMPOUND AS C-MET/AXL INHIBITOR
    Publication number: 20210371395
    Abstract: Provided are a uracil compound represented by Formula (IV) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition of the same. Also provided is a use thereof as a c-MET/AXL inhibitor in preparing a c-MET/AXL-inhibiting drug or a drug for treating a tumor.
    Type: Application
    Filed: November 23, 2018
    Publication date: December 2, 2021
    Applicant: MEDSHINE DISCOVERY, INC.
    Inventors: Jinping LI, Xiongbin XU, Gang LI, Lihong HU, Charles Z. DING, Yaling ZHOU, Guoping HU, Jian LI, Shuhui CHEN
  • Biphenyl compound as CCR2/CCR5 receptor antagonist
    Patent number: 11155523
    Abstract: Provided is a CCR2/CCR5 receptor antagonist and the use thereof in the preparation of a drug for treating diseases associated with the CCR2/CCR5. In particular, disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: October 26, 2021
    Assignee: Medshine Discovery, Inc.
    Inventors: Yunfu Luo, Yuyong Ba, Shuhui Chen
  • PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVES SERVING AS SELECTIVE HER2 INHIBITORS AND APPLICATION THEREOF
    Publication number: 20210323979
    Abstract: The present invention relates to a group of pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and an application thereof in the preparation of a drug that serves as an HER2 inhibitor. Specifically, the present invention relates to a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 8, 2019
    Publication date: October 21, 2021
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Kevin X CHEN, Fen JIANG, Xinde CHEN, Li ZHANG, Zhaoguo CHEN, Yanxin YU, Kai ZHOU, Boyu HU, Cheng XIE, Shuhui CHEN
  • CXCR2 antagonist
    Patent number: 11136315
    Abstract: A compound as a CXCR2 antagonist and an application thereof in preparing a drug as a CXCR2 antagonist. In particular, the present invention relates to a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: October 5, 2021
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Bin Chen, Xiawei Wei, Xuefeng Sun, Lei Zhang, Zhaoying Xu, Wenli Li, Peng Zhang, Feng Gao, Yunfu Luo, Jian Li, Shuhui Chen
  • SALT AND CRYSTAL FORM OF MODIFIED ANDROGRAPHOLIDE COMPOUND AND PREPARATION METHOD THEREOF
    Publication number: 20210284630
    Abstract: The present invention provides a salt and crystal form of a modified andrographolide compound and a preparation method and pharmaceutical use thereof.
    Type: Application
    Filed: May 24, 2018
    Publication date: September 16, 2021
    Applicants: MEDSHINE DISCOVERY INC., HEILONGJIANG ZHENBAODAO PHARMACEUTICAL CO, LTD
    Inventors: Jianhua XIA, Zhigan JIANG, Haiying HE, Jing WANG
  • [1,2,4]triazolo[1,5-c]pyrimidine derivative as Areceptor inhibitor
    Patent number: 11117899
    Abstract: Provided are a compound represented by formula (I), an isomer or a pharmaceutically acceptable salt thereof, and an application of the same in preparing a drug for treating a disease related to A2A receptor. The R1, R2, R3, ring A, ring B, n, and m are as defined in the specification.
    Type: Grant
    Filed: April 8, 2018
    Date of Patent: September 14, 2021
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Kevin X Chen, Yanxin Yu, Xinde Chen, Li Zhang, Zhaoguo Chen, Cheng Xie, Xiaofei Wang, Linghui Wu, Guoping Hu, Jian Li, Shuhui Chen